About US
Contact us
-
Xellia Pharma buys former Boehringer Ben Venue plant, once the poster child of quality failingsDenmark's Xellia Pharmaceuticals has bought the formerBen Venueplant, at one time the most notorious U.S. plant underFDAsupervision, and the facility responsible for dozens of recalls and a slew of dr2015/11/30
-
Turing offers discounts instead of cutting controversial list price on DaraprimTuring Pharmaceuticalshas been saying for a while now that it would lower the price of its toxoplasmosis med, Daraprim, responding to growing backlash from lawmakers and the public after it bought the2015/11/30
-
Mylan may soon find itself wrestling former target Perrigo for dealsEarlier this month, Perrigo ($PRGO) shareholders spurned a hostile buyout attempt from Mylan ($MYL). And now, the Netherlands-based company may have to go up against its former target if it wants to p2015/11/27
-
Xellia Pharma buys former Boehringer Ben Venue plant, once the poster child of quality failingsDenmark's Xellia Pharmaceuticals has bought the formerBen Venueplant, at one time the most notorious U.S. plant underFDAsupervision, and the facility responsible for dozens of recalls and a slew of dr2015/11/27
-
FDA approves BMS' Opdivo for kidney cancer a week after granting priority reviewIn another striking FDA turnaround for Bristol-Myers Squibb's ($BMY)Opdivo, the agency has approved it for treating advanced renal cell carcinoma just a week after granting priority review. The agenc2015/11/24
-
With veteran job-choppers Pfizer and Allergan joining hands, how many layoffs are in the cards?Both Pfizer ($PFE) and Allergan ($ACT) have a history of doing "transformational" deals--and those can come along with serious layoffs. So now that they've joined hands in a $160 billion merger agreem2015/11/24
-
Takeda's Velcade successor gets quick FDA approvalJust a couple of months after accepting the application, theFDAhas approvedTakeda Pharmaceutical's Ninlaro, a treatment for multiple myeloma that the Japanese company hopes can get established before2015/11/23
-
Novartis snags new approvals for Cosentyx in EuropeNovartis ($NVS) has been jockeying for additional uses for its next-gen psoriasis med,Cosentyx, hoping that a trifecta of indications will help generate blockbuster sales and distinguish the drug from2015/11/23
-
Adapt's new bargain-priced OD antidote enters contentious marketThe rising number of opioid-related deaths in the U.S. has translated into big opportunity for pharmas selling the antidote med naloxone, with drugmakers such as Amphastar Pharmaceuticals ($AMPH) gett2015/11/20
-
Pfizer prepared to risk a 3% breakup fee for chance at Allergan, sources tell ReutersBreaking up can be hard to do. It can also be expensive, which would be the case for Pfizer if the roughly $150 billion deal it is reportedly negotiating with Allergan were to go south. But the potent2015/11/20